

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.
Dated: February 28, 2005 Signature: *Diane Bergin*
(Diane Bergin)

Docket No.: 61683-00004USPT
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Charles R. Stewart et al.

Application No.: 10/809761

Confirmation No.: 8658

Filed: March 25, 2004

Art Unit: 1653

For: ANTI-MICROBIAL PROTEINS FROM THE
SPO1 BACTERIOPHAGE

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing of a first Office Action on the merits. A copy of each non-patent literature reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith to our Deposit Account No. 13-0480, under Order No. 31999999-700016.

Dated: February 28, 2005

Respectfully submitted,

By 

Tamsen Valoir, Ph.D.

Registration No.: 41,417

BAKER & McKenzie LLP

Pennzoil Place, South Tower

711 Louisiana, Suite 3400


Houston, Texas 77002-2746

U.S.A.

Tel: +1 713 427 5028

Fax: +1 713 427 5099

Attorneys For Applicant



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/809761
		Filing Date	March 25, 2004
		First Named Inventor	Charles R. Stewart
		Art Unit	1653
		Examiner Name	Suzanne Marie Mayer
Sheet 1	of 3	Attorney Docket Number	61683-00004USPT

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BARRETT, J.F. et al., Antibacterial agents that inhibit two-component signal transduction systems, Proc. Natl. Acad. Sci. USA, April 1998, pp. 5317-22, Vol. 95.	
	C2	BISWAS, B. et al., Bacteriophage Therapy Rescues Mice Bacteremic from a Clinical Isolate of Vancomycin-Resistant Enterococcus Faecium,	
		Infection and Immunity, Jan. 2002, pp. 204-210, Vol. 70(1).	
	C3	BREITHAUPT, H., The new antibiotics - Can novel antibacterial treatments combat the rising tide of drug-resistant infections?,	
		Nature Biotechnology, Dec. 1999, pp. 1165-1169, Vol. 17.	
	C4	DREWS, J., Drug Discovery: A Historical Perspective, Science, Mar. 2000, pp. 1960-1964, Vol. 287.	
	C5	DIXON, B., Genomics and Innovation in Antibiotics, ASM News, 2002, pp. 106-7, Vol. 68.	
	C6	EINARSON, M. et al., Identification of Protein-Protein Interactions with Glutathione-S-Transferase Fusion Proteins,	
		Cold Spring Harbor Laboratory Press, 2001, pp. 37, 57.	
	C7	ERDMANN, J., Bacteria Resistant to Drugs Draw Scrutiny of Biofirms, Genetic Engineering News, May 1999, pp. 1, 19, 50, 58; Vol. 19(10).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	3	Application Number	10/809761
				Filing Date	March 25, 2004
				First Named Inventor	Charles R. Stewart
				Art Unit	1653
				Examiner Name	Suzanne Marie Mayer
				Attorney Docket Number	61683-00004USPT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C8	GLASER, V., Rational Drug Design Plays Big Part in Drug Discovery, Genetic Engineering News, Nov. 1, 1998, pp. 1, 8.	
	C9	GOLEMIS, E., Protein-Protein Interactions - A Molecular Cloning Manual, Cold Spring Harbor Laboratory Press, 2002, 2 pp.	
	C10	HARWOOD, C. et al., Molecular Biological Methods for Bacillus, 1990, 2 pp., John Wiley & Sons Ltd, West Sussex, England.	
	C11	JOHNSON, C. et al., Novel antimicrobial targets from combined pathogen and host genetics, PNAS, Feb. 2000, pp. 958-9, Vol. 97(3).	
	C12	MILLER, J., A Short Course in Bacterial Genetics, Cold Spring Harbor Laboratory Press, 1992, 2 pp.	
	C13	PERSIDIS, A., Antibacterial and antifungal drug discovery, Nature Biotechnology, Nov. 1999, pp. 1141-2, Vol. 17.	
	C14	SAMPATH, A. et al., Genetic Analysis of Host-takeover in SPO1 infection of B. subtilis, Abstracts of the Fourteenth Evergreen International Phage Biology Meeting,	
		Aug. 2001, Poster Section, p. 9.	
	C15	SAMPATH, A. et al., Role of SPO1 Genes 44, 50, and 51 in Host-takeover and Bacterial Cell Death, Abstracts of the Fourteenth Evergreen International Phage Biology Meeting,	
		Aug. 2001, p. 5.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/809761
		Filing Date	March 25, 2004
		First Named Inventor	Charles R. Stewart
		Art Unit	1653
		Examiner Name	Suzanne Marie Mayer
Sheet 3	of 3	Attorney Docket Number 61683-00004USPT	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C 16	SHAMOO, Y. et al., Crystal structure of the two RNA binding domains of human hnRNP A1 at 1.75 A resolution, Nature Structural Biology, Mar. 1997, pp. 215-222, Vol. 4(3).	
	C 17	ZHANG, H. et al., New Perspectives on Anti-HER2/Neu Therapeutics, Drug News Perspect, Aug. 200, pp. 325-9, Vol. 13(6).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.